SCHERING-PLOUGH PROVENTIL 1994 SALES INCREASE 12% TO $396 MIL. DESPITE GENERIC COMPETITION FOR NON-INHALER DOSAGE FORMS; MMD FIRST QUARTER SALES FLAT
Executive Summary
Sales of Schering-Plough's Proventil albuterol asthma therapy line increased 12% in 1994 to $396 mil., Chairman Robert Luciano told Schering-Plough's annual shareholders meeting April 25 at the company's Kenilworth, N.J. headquarters